Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Share-based Compensation (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Share-based Compensation for 11 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 24.24% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, up 36.92% year-over-year, with the annual reading at $3.8 million for FY2025, 36.92% up from the prior year.
  • Share-based Compensation hit $1.0 million in Q4 2025 for vTv Therapeutics, up from $1.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.0 million in Q4 2025 to a low of $167000.0 in Q2 2022.
  • Historically, Share-based Compensation has averaged $586900.0 across 5 years, with a median of $463000.0 in 2021.
  • Biggest five-year swings in Share-based Compensation: tumbled 70.72% in 2022 and later surged 269.55% in 2025.
  • Year by year, Share-based Compensation stood at $994000.0 in 2021, then crashed by 70.72% to $291000.0 in 2022, then surged by 38.49% to $403000.0 in 2023, then surged by 104.71% to $825000.0 in 2024, then rose by 24.24% to $1.0 million in 2025.
  • Business Quant data shows Share-based Compensation for VTVT at $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $930000.0 in Q2 2025.